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Case presentation
A previously healthy 12-year-old boy, one of 6 children, developed
facial and peripheral edema, dark urine, decreased urinary output, and
elevated blood pressure; his pediatrician referred him to the Hospital
Universitario de Maracaibo. Six weeks prior to admission the patient
had skin infections on his legs. Three weeks later he complained of a
sore throat and was given oral tetracycline for 5 days. He received no
other medications and had no history of ingestion of any toxic material.
His family lived on the outskirts of the city in inadequate housing with
poor sanitation.
On admission, the boy was alert and apprehensive. His blood
pressure was 140/90 mm Hg; heart rate, 88/mm; respiratory rate, 22/
mm; temperature, 37°C; and weight, 29.9 kg. He complained of a dull
ache in the lumbar area, and he was more comfortable in a sitting than
in a lying position. His face was puffy and he had 1 + pitting edema
below the knees. His lungs were clear and his heart was not enlarged. A
loud second aortic sound and a soft basal systolic murmur (grade II/V)
were noted. Some tenderness in the right upper quadrant of the
abdomen was evident, but liver, spleen, and abdominal masses were
not felt. Neurologic examination, including level and state of conscious-
ness, was within normal limits.
Initial laboratory determinations yielded the following. Urinalysis
revealed a specific gravity of 1.010, a pH of 6.0, 1 + proteinuria, and
abundant red blood cell casts in the sediment. His hemoglobin was 10.8
g/dl and the blood smear showed microcytosis; the mean red cell
volume was 70 fi, the mean corpuscular hemoglobin concentration was
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20 mmol/liter, and the reticulocyte count was 1%. The white blood cell
count was 7800/mm3 with a normal differential, Serum creatinine was
1.1 mg/dl; serum sodium, 138 mEq/liter; and serum potassium, 4.5 mEq/
liter. Urinary creatinine was 61.9 mg/dI; sodium, 57 mEq/liter; and
osmolality, 747 mOsm/liter. Serum C3 levels were 45 mgldl (normal 140
22 mgldl); antistreptolysin 0 titer, 240 Todd units (normal < 240 Todd
units); antihyaluronidase titer, 1:1024 (normal < 1:512); and strepto-
zyme test, 1:400 (normal 1:200). Serum IgG was 1800 mg/dl (normal <
1100 210 mgldl); serum 1gM, 200 mg/dl (normal 125 30 mgldl); and
serum IgG, 170 mg/dl (normal 160 80 mgldl). Antinuclear antibodies
and LE cell preparations were negative, and serum cryoglobulins were
positive after being incubated at 4°C for 5 days. Standing plasma renin
activity was 0.33 ng/ml/hour, and plasma aldosterone was 15 pg/mI.
Blood sugar, cholesterol, uric acid, calcium, and phosphorus levels
were within normal limits. Serum iron was 55 mgldl; total iron binding
capacity, 420 mg/dl; and percentage of transferrin saturation, 15%.
Chest x-ray showed hilar congestion, but the size of the cardiac
silhouette was normal. The stool was negative for parasites. Cultures
were taken from the throat and the skin lesions, and the patient was
given 1,200,000 units of penicillin intramuscularly. The cultures did not
grow J3-hemolytic streptococci.
During the first 24 hours, urine output was 452 ml, and the creatinine
clearance, corrected for 1.73 m2 surface area, was 30 mi/mm. The urine
was refrigerated during collection, and the following determinations
(excretion per day) were done: urinary sodium, 25.8 mEq; urinary
potassium, 46 mEq; urinary kallikrein, 5.6 esterase units (EU); urinary
PGE2, 4.46 ng; and urinary aldosterone, 1.6 .tg/day.
During the first 24 hours, all fluids and foods were withheld; by the
end of that period, the blood pressure had decreased to 140/80 mm Hg.
A diet containing only 10 mEq/day of sodium was instituted on the
second hospital day, and fluid intake was restricted to less than 500 ml
daily. Activity was not restricted. A diuresis, begun on the third
hospital day, produced a urine output of 900 ml on that day. The
remainder of the hospital course was uneventful and the patient was
discharged after 4 weeks; he was given oral iron therapy. Renal biopsy
was not done. After discharge, microscopic hematuria persisted (8 to 10
red blood cells per high-power field), but the blood pressure was 90/60
mm Hg, the weight fell by 2.4 kg, and edema disappeared. The serum
creatinine was 0.8 mg/dl; creatinine clearance, 143 mi/mm; and serum
C3 level, 100 mg/dl. The plasma renin activity (while the patient still
was eating a low-sodium diet) was 3.19 ng/ml/hour, and plasma aldos-
terone was 47.0 pg/mI. The daily aldosterone excretion was 48 g, and
urinary kallikrein and PGE2 excretion were 4.6 EU/day and 6.1 ng/day,
respectively.
The patient's family members were examined weekly after the patient
was hospitalized. All siblings demonstrated significant increases in the
titer of streptozyme test and/or antihyaluronidase titer in the following 5
weeks. A 6-year-old sister also developed microscopic hematuna, and
serum C3 levels fell to 80 mg/dl, but she had no symptoms and no
hypertension. She was managed as an outpatient, and she experienced
no complications. After 4 weeks her C3 levels returned to normal.
Discussion
DR. BERNARDO RODRIGUEZ-ITURBE (Professor of Medicine,
Servicio de NefrologIa, Hospital Universitario de Maracaibo,
Maracaibo, Venezuela): This 12-year-old boy developed the
acute nephritic syndrome (ANS) after pyoderma and a sore
throat. Antistreptococcal antibody titers were elevated and the
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entire clinical picture resolved without complications. In addi-
tion, his sister had subclinical or latent nephritis with serologic
evidence of preceding streptococcal infection. I have little
doubt about the diagnosis of acute poststreptococcal glomerulo-
nephritis (APSGN) in this case. Therefore I will devote my
comments to several aspects of the ANS and APSGN exempli-
fied by this patient rather than discuss other diagnostic possibil-
ities. Similarly, I will not discuss his moderate iron-deficiency
anemia, an anemia that in this part of the world is usually of
nutritional origin and frequently is associated with intestinal
parasites.
The diagnosis of ANS in this patient is based on the existence
of its classic features: oliguria, edema, hematuria, and hyper-
tension. Acute nephritic syndrome is the typical clinical presen-
tation of the glomerulonephritis that follows streptococcal
infection. In this case, the poststreptococcal cause is suggested
by the history and is confirmed by the elevation of antihyalur-
onidase and streptozyme test titers. There are no significant
differences in the frequency of presentation of the clinical
features of the ANS in sporadic versus epidemic cases of
APSGN. The complete clinical picture appeared in less than
40% of the 1610 patients we have seen with APSGN [1]. Edema
is the finding most commonly present in patients with APSGN,
existing in 85% and constituting the chief complaint in 62%.
Anasarca is present in 36% of the children between 2 and 6
years of age, and only in 7% of the patients older than 12 years.
Macroscopic hematuria appears in roughly 30% of the patients
[1]; diastolic hypertension occurs in 82%, but in only 50% is the
diastolic blood pressure greater than 30 mm Hg above normal.
A child of 12 should have a diastolic blood pressure less than 80
mm Hg [2}, a value similar to the blood pressure of this patient
at the time of discharge. It is interesting that our patient
complained throughout his hospital course of a dull lumbar
ache; this type of discomfort, although unusual, occurs in 5% to
10% of patients [3, 4]. The pain or ache traditionally has been
attributed to distension of the renal capsule by parenchymal
edema [5].
In addition to the presentation of ANS, poststreptococcal
nephritis can be subclinical, as I will discuss later, or it can have
the manifestations of nephrotic syndrome or the clinical course
of rapidly progressive glomerulonephritis with early irreversible
uremia. The latter two forms of clinical presentation are rare.
Nephrotic syndrome appears in less than 4% of the patients
with epidemic or sporadic disease; a rapidly progressive course
to uremia occurs in less than 0.5% of the sporadic cases and is
even rarer in epidemic APSGN.
In acute glomerulonephritis, the urinary "diagnostic indices"
usually are consistent with prerenal failure [6]. In this patient,
fractional sodium excretion was 0.73%, the U/P creatinine ratio
was 56.3, and the so-called renal failure index (urinary sodium
divided by U/P creatinine [7]) was 1.01; all these data are
consistent with the diagnosis of acute nephritis [6].
The pathophysiologic chain of events responsible for the
ANS is shown in Figure 1. The inflammatory damage to the
filtration surface results in a decrease in glomerular filtration
rate (GFR). An increase in ultrafiltration pressure, induced by
the usual reduction in colloid osmotic pressure [81, partially
offsets the decline in GFR. Observations in rats with experi-
mental nephritis show that the absolute proximal reabsorption
of sodium is lower (because of a reduction in peritubular
oncotic pressure) than in normal animals for each level of GFR;
nevertheless, a decrease in distal delivery with constant or
increased distal reabsorption is present and, as a result, sodium
is retained [9]. As noted in Figure 1, a critical level of sodium
intake is needed to maintain positive sodium balance which, in
turn, is responsible for the extracellular volume expansion and
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Table 1. Humoral determinations in the acute nephritic syndrome
(ANS)a
Control
(N =
Mean
group
10)
SEM
Patients
ANSb
Mean SEM
(N = 13)
Discharge
Mean SEM
Standing PRA
(ng/ml/hr) 5.32 0.68 1.13 0.29d 5.45 0.84
Plasma aldosterone
(pg/mi) 117.0 13.2 81.6 23.2" 289.3 52.2
Urinary PGE2
(ng/kg/day) 2.06 0.43 0.91 0.28 0.93 0.21
Urinary PGF
(ng/kg/day) 7.10 1.07 3.56 0.66' 10.51 5.0
Urinary kallikrein
(pE U/kg/day) 0.49 0.1 0.14 0.44" 0.26 0.09e
Data in the table are from Refs. 1, 10, and 11.
ANS refers to acute nephritic syndrome.
PRA refers to plasma renin activity.
"P <0.001.
P < 0.05 (versus control group).
suppression of plasma renin and aldosterone.
Table 1 depicts the value of several humoral determinations
obtained in 13 of our patients. As expected (10—12], the renin-
aldosterone system was suppressed during the acute nephritic
syndrome, which was characterized by extracellular volume
expansion. In the patient presented today, plasma renin activity
(PRA) and plasma and urine aldosterone responded normally to
the low-salt diet at the time of discharge 4 weeks after admis-
sion. Determinations of PGE2, PGF2a, and kallikrein in the
urine on admission were depressed (Table 1). In contrast to the
PRA and aldosterone levels, the urinary excretion of PGE2 and
kallikrein was still depressed 4 to 6 weeks after admission
(Table 1). These findings are in agreement with our preliminary
data [13] and with the results of studies of kallikrein excretion in
rats with experimental nephritis [14].
Although urinary excretion of prostaglandins and kallikrein
does not equal the rate of synthesis, the reasons for a depres-
sion of this system in ANS—a depression that lasts for several
weeks even after the patient has recovered clinically—are
unclear. Hemodynamic factors could be playing a role in the
acute expanded state, but not at the time of convalescence.
Similarly, interrelations with the renin-angiotensin axis proba-
bly are not responsible, because this system and the prostaglan-
din-kallikrein systems clearly are dissociated in the convales-
cent stage. It is unlikely that the findings of decreased esteroly-
tic activity in the urine could be due to the presence of kallikrein
inhibitors in the urine, because Glasser and Michael eliminated
this possibility in their experimental studies [14]. For lack of a
better explanation, one should consider the possibility that the
inflammatory lesion in the glomerulus might be responsible for
these findings; yet it is not readily apparent how a glomerular
lesion could alter the production or excretion of prostaglandin
and kallikrein. It is also not clear whether the depression of this
system has any role in the pathophysiology of the acute
nephritic syndrome.
Immunologic findings. The serologic findings in today's
patient all were consistent with the diagnosis of APSGN. The
levels of serum IgG, 1gM, and Clq binding activity were
increased, serum C3 levels were depressed, and cryoglobulins
were present. In 119 patients with APSGN that we studied,
more than 90% had elevated serum levels of lgG and ig; in
89%, C3 levels were depressed; and cryoglobulins were detect-
ed in 66% of patients in the first few weeks of the illness [15,
16]. Rheumatoid factor titers were negative in the serum of
today's patient; a positive rheumatoid factor was initially
reported present in most patients [17], but has been found in
slightly less than 50% of the patients in more extensive series
[1]. The discrepancy in these results probably is related to a
lower sensitivity of tests done with commercially available kits
[16] than those carried out in a laboratory with a research
interest in anti-immunoglobulins [17].
A streptococcal cause of the glomerulonephritis in this child
is strongly suggested by the elevated antihyaluronidase and the
streptozyme studies. Serologic evidence of streptococcal infec-
tion is the usual ground for establishing a streptococcal patho-
genesis because a positive culture for group A streptococcus is
found in only 20% of patients with APSGN (diagnosed by the
clinical picture of ANS following skin or throat infection
accompanied by elevation of antistreptococcal antibody titers)
[4]. The antibiotic treatment that the patient received prior to
admission to the hospital, although unconventional for a strep-
tococcal infection, could have been responsible for the negative
cultures. I assume, in accord with the careful studies of
Anthony et al [18], that the patient under discussion today had
the same bacteria in both skin and pharynx, and that the skin
infection preceded the throat infection.
The nature of the nephritogenic antigen, that is, the strepto-
coccal antigenic fraction responsible for nephritis, remains the
subject of controversy. Various antigenic materials derived
from streptococci have been implicated, and available studies
were authoritatively reviewed by Zabriskie et al in 1973 [19].
Any potential nephritogenic antigen should meet at least the
following three criteria: (1) It should be present in group A
streptococci isolated from patients with APSGN and should be
absent in nonnephritogenic bacteria. Clearly, the nonnephrito-
genicity of a streptococcus is always open to question because
its isolation from a patient without nephritis also could be due to
host resistance. Inasmuch as the coexistence of nephritis and
rheumatic fever is extremely rare, it might be better to require
that a potential nephritogen be absent in streptococci isolated
from patients with rheumatic fever; (2) The material also should
be demonstrable in the renal biopsy specimens from patients
with APSGN. It has been difficult to find specific antigens in the
biopsy specimens of patients with APSGN, perhaps because
the time of biopsy is critical; antigenic sites can be masked by
antibodies after only 7 days [20]; (3) Antibody to the proposed
antigen should be detectable in the serum of patients with
APSGN.
At present, three antigenic fractions obtained from nephrito-
genic streptococci are the major focus of investigation. The first
is the New York Medical College antigen (Endostreptosin,
water-soluble preabsorbing antigen), isolated from the superna-
tant recovered after centrifugation of bacteria that were subject-
ed to disruption by a Ribi cell disintegrator or by a Braun
mechanical cell homogenizer [20—221. Investigators have shown
that convalescent sera contain antibodies which, if marked with
fluorescein, stain biopsies taken very early in the course of the
disease [20—22]. These antibodies presumably are directed
against the nephritogenic fraction. Therefore, the streptococcal
antigens recovered from nephritogenic strains were screened
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for their ability to block the staining capacity of convalescent
sera. The blocking or "preabsorbing" fraction, purified by
column chromatography, has a molecular weight of about
50,000 daltons. Antibody levels to this antigen have been shown
in all patients with APSGN but also in 10% to 74% of normal
individuals [21, 22]. The possibility that this material acts as a
"planted" antigen was raised recently [231.
The second antigenic fraction of current interest is the
nephritis-associated streptococcal antigen described by the
Rockefeller University group [24, 25]. This antigen is a protein
of 49,000 daltons that appears exclusively in supernatants of
cultures of nephritogenic streptococci. The protein, purified
through a carboxymethyl cellulose column, was detected in
66% of renal biopsy specimens from patients with APSGN. By
contrast, the antigen was not found in biopsy tissue from
patients with other glomerulonephritides or with rheumatic
fever. Antibody levels were detected in 93% to 96% of patients
with APSGN, in 5% to 15% of the patients with rheumatic
fever, and in 13% to 20% of normal individuals.
The third, the cationic nephritogenic antigen(s), were isolated
by Vogt et al from culture supernatants of nephritogenic
streptococci and subsequent separation of the protein fractions
by chromatofocusing [26]. This technique allows elution of the
fractions with descending pH gradients and yielded several
antigens in the pH range of 8 to 11. Cationic antigen(s) were
detected in 8 of 18 biopsy specimens from patients with APSGN
but were not found in 7 biopsy specimens from patients with
IgG-positive, non-APSGN glomerulonephritis. Antibodies to
cationic antigens were demonstrated in the serum of all 18
patients with APSGN tested. If the pathogenic immune com-
plex in this disease is formed in situ, as suggested by Lange and
coworkers [23], a cationic antigen is clearly a good candidate
for penetrating the negatively charged glomerular barrier and
for acting as a planted" target for the antibody. From the
preceding comments it is clear that the three antigenic fractions
discussed all meet the criteria for a potential nephritogen that I
mentioned earlier.
In addition to exogenous streptococcal antigens inducing
immune-complex disease, the possibility of an autologous im-
mune complex pathogenesis is raised by the experimental work
of McIntosh and colleagues [27]. According to this hypothetical
construct, streptococcal neuraminidase removes sialic acid
from immunoglobulins which, in turn, become autoantigenic.
The finding of circulating [15] and glomerular fixed [28] anti-
globulins in APSGN favors this possibility. Anti-IgG reactivity
also was found in the IgG eluted from the kidney of a patient
with APSGN [29], and lymphocytic reactivity for human IgG,
suggestive of antigenic recognition, was found in skin-window
tests performed in patients with APSGN and rheumatoid arthri-
tis [30].
We studied sera from 39 patients with APSGN and found
thiobarbituric acid-reactive material, presumably free sialic
acid, in 28 and neuraminidase activity in 8 [31]. Potter et at
evaluated sera from 12 patients from Trinidad, 6 patients with
APSGN and 6 patients with rheumatic fever, and could not
detect neuraminidase activity in any of them; increased levels
of free sialic acid were found in 2 of the patients with APSGN,
but also in 2 of the patients with rheumatic fever [32].
Davies, Baig, and Ayoub reported neuraminidase production
by M-type streptococci of types usually associated with nephri-
Table 2. Subclinical acute poststreptococcal glomerulonephritis
Study Patients
Ratio of
subclinical
to clinical
disease
Dodge et at, 1967 [40] Families of index cases 5.3
Anthony et at, 1969 Epidemic APSGN, 1.5
[43] general population
Sharrett et al, 1971 Household members of 0.03—0.59
[421 index cases
Sagel et at, 1973 [391 Outpatient clinic,
nonfamilial study
19.0
RodrIguez-lturbe et First-degree relatives 4.0
at, 1981 [411 of index cases
tis, such as type 1, 4, and 12 [32]. These observations were
confirmed by Potter et at, but they could not detect neuramini-
dase production in streptococci isolated from patients with
APSGN [32]. Contrary to these findings, we found that 16 of 20
streptococci cultured from patients with APSGN in Maracaibo
did produce this enzyme (Mosquera J, Katiyar V, Coello J,
RodrIguez-Iturbe B, unpublished observations). The different
results could be due to loss of the capacity for enzyme
production by the bacteria over time after repeated
subculturing.
The observations I have summarized appear to indicate that
some patients with APSGN have anti-immunoglobulin reactiv-
ity that might be neuraminidase induced. Some of the data are
conflicting and, clearly, the last word has not been said on the
subject. Any of the mechanisms and antigens I have discussed
might be of primary importance in APSGN; alternatively, any
or all could be epiphenomena.
A renal biopsy was not performed in the patient we are
discussing, and in fact I believe that the procedure was not
justifiable on clinical grounds. A biopsy would have added little
to the diagnosis, treatment, or prognosis in this patient. If a
biopsy had been performed, it probably would have shown a
proliferative endocapillary glomerulonephritis with IgG, 1gM,
and C3 deposits. Not even subepithelial electron-dense deposits
or "humps," the most typical lesion, is diagnostic of APSGN.
"Humps" also have been found in lupus erythematosus [34],
malaria [35], bacterial endocarditis [36], cryoglobulinemia [37],
and membranoprotiferative glomerulonephritis [38]. Because a
sister of the patient had asymptomatic glomerulonephritis, I
would like to discuss the subclinical manifestations of this
disease and the familial susceptibility for APSGN.
Subclinical acute poststreptococcal glomerulonephritis. Sev-
eral studies have noted the development of glomerulonephritis
in asymptomatic patients (Table 2). Sagel et at prospectively
followed children as outpatients after streptococcal infections
and performed renal biopsy in all manifesting depressed serum
complement levels. The authors found that lesions of glomeru-
lonephritis were present in all patients in whom the serum
complement decreased and hematuria appeared [39]. There-
fore, the diagnosis of subclinical disease is based on the
demonstration of microscopic hematuria and transient fall of
the serum complement 2 to 4 weeks after a streptococcal
infection. Occasionally, hypertension is also found. Sagel et at
[39] found that subclinical disease was 19 times more common
than was clinical APSGN in unrelated children. Dodge, Spargo,
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and Travis found a ratio of subclinical to clinical disease of 5.3
[40], a figure similar to the ratio of 4.0 in our own familial
studies [41]. Sharret et al reported the ratio to be only 0.03, but
in this study serial testing of the household members was not
done and therefore subclinical disease was probably underesti-
mated [42]. The Red Lake study of 1966 found subclinical
disease to be 1.5 times more common than was clinical APSGN
[43], and I believe this is the only report available that studied
the general population under epidemic conditions. The studies
summarized in Table 2 indicate that cases of subclinical glomer-
ulonephritis are several times more frequent than are sympto-
matic cases. At present, there are no reports on the long-term
prognosis of these asymptomatic patients.
Familial studies. Cases of APSGN frequently cluster in an
individual family. Dodge and coworkers reported that 20% of
the sibling contacts of patients with APSGN developed either
clinical or subclinical glomerulonephritis [40]. We studied 22
families (141 first-degree relatives) of index cases of APSGN
and found that 72 sibling contacts at risk developed nephritis as
judged by repeated examination, urinalysis, serum comple-
ment, and antistreptococcal antibody determinations; the at-
tack rate was 37.8% [41]. Both these studies were performed on
sporadic cases. In the Red Lake epidemic I referred to earlier,
Anthony et al reported nephritis, a urinary abnormality, or both
in 28.3% and 4.5% of the patients who had skin and throat
infections, respectively [43].
Because of the high attack rate of nephritis in families, we
had suggested that a familial trait might be involved in one's
susceptibility to the disease [41]. Subsequent studies in families
give a proportion of affected children of 0.260 0.016 after
appropriate correction for incomplete selection in the sibships
[44]; this finding is an excellent fit for a single autosomal
recessive inheritance, but clearly genetic proof cannot be given
at present.
Several studies have analyzed the association of poststrepto-
coccal disease with HLA antigens, but so far no clear relation-
ship has emerged. Read et a! found that the HLA distribution in
patients with APSGN is similar to that in the general population
[45], whereas studies of rheumatic fever patients have found a
decreased frequency of HLA-A3 [46], an increased incidence of
HLA-BW35 [47], and linkage disequilibrium of HLA-B5 [45].
We investigated HLA antigens in APSGN and found that the
incidence of HLA-CW5 and DR3 deviated from the expected
1:1 ratio in affected siblings in families [48]. Control groups
studied included unaffected siblings and unrelated children. In
addition, HLA-DRW4 showed an increased frequency in unre-
lated APSGN patients. Further studies are required to establish
a relationship between HLA antigens and susceptibility to
APSGN.
In regard to treatment, most children with APSGN need little
or no medication. Parenteral antihypertensive therapy (diazox-
ide or hydralazine) is required only in patients with severe
hypertension—in our experience, in less than 20% of the
patients [4]. We routinely withhold liquids and food for 24
hours, even in mild cases, because fasting promotes negative
salt-and-water balance and is a safe regimen to follow until the
volume of urinary output is ascertained [49]. Congestive heart
failure, although rare, may require tourniquets or venisection.
Digitalis is ineffective and diuretics, with the possible exception
of furosemide, are not effective.
Table 3. Follow-up studies of patients with acute poststreptococcal
glomerulonephntis of more than 2 yearsa
Chronic
Years renal
of Epidemiologic failure
follow- characteristics of Cases/total
Authors up APSGN followed
Perlman et al 10 Epidemic-symptomatic 0/61
[53]
Travis et al [54] 2—5 Sporadic-symptomatic 1/54
Baldwin et al 2—17 Sporadic-symptomatic 6/176
[50, 52, 56]
Lien et al [571 2—14 Sporadic-symptomatic 0/57
Potter et al 12—17 Epidemic and endemic 1/534
[58, 59] Symptomatic and
subclinical
Maracaibo 11—12 Epidemic-symptomatic 1/71
studies [51,
60]
a Table modified from Ref. 14. Only the later studies o f each group
were used to assess the last column.
Because there is no proof that bed rest improves the progno-
sis, we do not impose it on our patients. The patient usually
prefers to rest in bed in a sitting position when admitted to the
hospital, but a feeling of well being returns after one or two
days. One should remember that the patient's level of con-
sciousness should be checked at regular intervals, particularly
during the first 24 hours [49], because encephalopathy, although
a rare complication, is a serious one that requires prompt
treatment. Encephalopathy has occurred in approximately
0.5% of our patients with APSGN. The association of acute
nephritis and encephalopathy should always raise the possibili-
ty of systemic lupus erythematosus. I will conclude my com-
ments by discussing the prognosis of APSGN.
Long-term prognosis. Universal agreement exists that the
short-term prognosis is excellent, the early mortality of APSGN
being approximately 0,5% [4], but the long-term prognosis is
controversial. Table 3 summarizes the follow-up studies of
APSGN of more than 2 years duration. Baldwin and coworkers
reported in 1974 that, as judged by clinical and histologic
criteria, the incidence of chronic renal disease in patients
followed 2 to 15 years after having APSGN exceeded 50% [50].
The biopsies showed sclerotic changes, and hypertension was
present in 18% to 47% of the patients 2 to 7 years after the acute
attack, and in 50% of the patients thereafter. Other groups
report abetter prognosis. Part of the disagreement might be due
to the method of defining progression to chronicity. For in-
stance, the incidence of glomerular sclerosis is far higher than
that of clinical or biochemical abnormalities [50, 51], but the
lesions can be interpreted either as a residual inactive finding or
else as evidence of progressive disease [52]. In addition, the
patient population is not uniform in the various series [52—60];
some patients might have had epidemic and some sporadic
disease (the latter probably having a worse prognosis), and
some might have had mild nephritis and some nephritis severe
enough to require hospitalization. Finally, the prognosis is
better in children than in adults [51].
If one chooses to view chronic renal failure as an indisputably
relevant end-point, it appears from the combined studies
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summarized in Table 3 that only 9 of 953 patients developed
terminal uremia after 10 to 12 years of follow-up. I therefore will
conclude by stating that this boy has less than a 1% chance of
having uremia one decade from now.
Questions and answers
DR. ALVIA GASKIN (Department of Pathology, Hospital
Universirario de Maracaibo): We are in a unique situation
because of the large number of patients with APSGN seen at
our institution. Should we be performing more biopsies, both in
the acute stage and as a means of studying the late course of the
patients?
DR. RODRfGUEZ-ITURBE: I am disinclined to advise renal
biopsy in patients with uncomplicated APSGN. In the acute
stage the prognosis is so good that the risk of biopsy, however
small, is difficult to justify. We did late renal biopsies in our first
follow-up study [51] because of the controversy raised by
Baldwin's study [50], and to evaluate histologic changes in
relation to the clinical picture. We could confirm Baldwin's
findings of very impressive pathologic changes. However, our
subsequent follow-up study showed a very low incidence of
uremia in our patients [60] (Table 3). Because of this and
because the histologic findings do not result in a change in
treatment, we do not do biopsies in asymptomatic patients to
study the late course of APSGN.
DR. GASKIN: I have two additional questions. First, in the
long-term follow-up series, were all the patients evaluated
according to the same criteria? Second, are the clinical manifes-
tations that are evident on admission related to the outcome?
DR. RODRIGUEZ-ITURBE: As I mentioned before, some of the
series utilized pathologic changes, some used creatinine clear-
ance, and some used examination of the urine and serum
creatinine. Of course, all studies included a careful history and
physical examination including blood pressure. Clearly, each
group's results are dictated by the characteristics of the follow-
up evaluation. With respect to your second question, the
answer is no; we have not detected a relationship between the
severity of hypertension, edema, or oliguria and the long-term
prognosis of the disease.
DR. CARLOS HENRIQUEZ (Renal Service, Hospital Universi-
tario de Maracaibo): Would you comment on the use of
diuretics and converting enzyme inhibitors in the acute nephrit-
ic syndrome?
DR. RODRIGUEZ-ITURBE: As far as I know, only furosemide
has been shown to be of any use. Powell, McCredie, and
Rotenberg showed that 2 mg/kg of furosemide induced a diure-
sis within 6 hours and corrected hypertension within 24 hours
[61]. The effect of furosemide on lowering the central venous
pressure also should be beneficial to cardiac function. With
respect to converting enzyme inhibitors, we have used captopril
in children with severe hypertension and edema, not so much
because it suppresses the renin-angiotensin system (it is already
suppressed), but in an attempt to obtain a beneficial effect
through the prostaglandin-kallikrein system. We found a re-
markable effect in the first 24 hours—blood pressure returned to
normal levels and a diuresis began. I cannot give you data on
humoral determinations as yet. I should point out that chronic
use of captopril has been linked to a few cases of membranous
nephropathy [62].
DR. JOHN T. HARRINGTON: Does treatment with penicillin
prevent APSGN?
DR. RODRIGUEZ-ITURBE: Penicillin therapy can be useful in
preventing the spread of streptococcal infection in certain
environments, such as military installations, but this treatment
has not been shown to prevent APSGN in a patient already
infected. Penicillin therapy would have to be given very early to
prevent an immune response. Given the high infectivity of
nephritogenic streptococcus and the high attack rate of APSGN
in families [44], I think it is reasonable if we treat the sibling
contacts of index cases of APSGN.
DR. ARTURO WONG (Nephrology Resident, Hospital Univer-
sitario de Maracaibo): Why does oliguria occur in only one-half
of the patients even though the other classic features of the
acute nephritic syndrome are much more frequent?
DR. RODRIGUEZ-ITURBE: I don't know why some findings are
more frequent than others. It is possible that we underestimate
the frequency of oliguria because the patient or the patient's
parents might not realize that the urine volume has decreased.
DR. LfRIM0 RuBlo PAEZ (Renal Department, Hospital Gen-
eral del Sur, Maracaibo): Has cellular immunity anything to do
with the long-term course of APSGN?
DR. RODRIGUEZ-ITURBE: I don't know of any data on that
point. Fillit and coworkers have shown altered lymphoblastic
responses to altered glomerular basement membrane in APSGN
[63], but few studies have dealt with cellular immunity in the
disease. Your question certainly deserves to be studied.
DR. HUMBERTO MORENO (Department of Genetics, Hospital
Universitario de Maracaibo): What is the mortality in the acute
stage, and how frequently do adults get APSGN? Second, if
nephritogenic streptococcus produces neuraminidase, could
one look for antineuraminidase antibody levels in the serum of
these patients?
DR. RODRIGUEZ-ITURBE: The mortality in the acute stage is
less than 1%. Large series of APSGN include about 10% adults.
To answer your second question, certainly that is a possibility,
but antineuraminidase antibody level testing has not been done,
to my knowledge.
DR. HARRINOTON: In the patient under discussion today, the
prostaglandin-kallikrein system was depressed on admission
and remained depressed during his convalescence, but the
renin-angiotensin system, also depressed on admission, was
responding normally to sodium deprivation during his convales-
cence. I wonder whether we can gain any insight into these
findings from the knowledge of what happens in other diseases,
such as cirrhosis, as spontaneous diuresis occurs.
DR. RODRIGUEZ-ITURBE: I cannot speculate on what bearing
the findings in cirrhosis might have on the acute nephritic
syndrome. As far as other types of renal disease are concerned,
a decreased excretion of these substances has been found in
some entities, such as lead nephropathy [64] and chronic renal
failure associated with hypertension [65]. The major problem in
explaining the changes in the prostaglandin-kallikrein system in
acute glomerulonephritis is the fact that these substances do not
have a major site of synthesis at the glomerular level. Neverthe-
less, similar findings have been reported in experimental neph-
rotoxic serum nephritis and aminonucleoside nephrosis [14],
but no clear explanation for the findings is available.
DR. PEDRO PAEZ BERMUDEZ (Department of Medicine,
Hospital Universitario de Maracaibo): Epidemics of glomerulo-
nephritis have followed scabies here as well as in other parts of
the world. Is there any information concerning the possibility
that scabies would predispose one to APSGN, perhaps by
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modifying skin components that could trigger an autoimmune
response?
DR. RODRIGUEZ-ITURBE: I am not aware of any studies
suggesting that possibility.
DR. HARRINGTON: Could the difficulty in finding the antigen
in APSGN be solved by the use of an animal model?
DR. RODRIGUEZ-ITURBE: The problem with APSGN is that
we find too many potential nephritogenic antigens. Several
investigators have isolated antigens that can be localized in the
kidney and that induce serum antibody levels. The difficulty is
choosing one of these antigens as responsible for the disease.
Maybe several nephritogenic antigens exist. Investigators have
tried for many years to induce APSGN by injecting streptococci
or parts of the bacteria or cultures, or polypeptides of those
cultures, using different methods of administration in various
experimental animals. The question is not whether nephritis can
be produced by these methods; clearly it can, because we are
injecting foreign protein. The issue is having an animal model
that resembles the human disease. Unfortunately, we do not
have that.
Reprint requests to Dr. B. RodrIguez-Iturbe, Servicio de Nefrologia,
Hospital Universitario de Maracaibo, Apartado Postal 1430, Maracai-
bo-Zulia 4001-A, Venezuela
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